ESPERION THERAPEUTICS INC. - COMMON STOCK

U.S. FDA Updates LDL-C Lowering Indication for Esperion’s NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet

13 Dec 2023 16:00:00 By Nasdaq GlobeNewswire

Esperion Presents CLEAR Outcomes Analysis of Inflammation as Predictor of Cardiovascular Risk at American Heart Association Scientific Sessions 2023

13 Nov 2023 10:30:00 By Nasdaq GlobeNewswire

Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American Heart Association 2023

11 Nov 2023 11:00:00 By Nasdaq GlobeNewswire

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

09 Nov 2023 16:30:00 By Nasdaq GlobeNewswire

Esperion Reports Third Quarter 2023 Financial Results

07 Nov 2023 06:00:00 By Nasdaq GlobeNewswire

Esperion to Participate in Jefferies London Healthcare Conference

31 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

Esperion to Report Third Quarter 2023 Financial Results on November 7

24 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

American College of Cardiology Program to Increase Cholesterol Screenings

12 Sep 2023 10:15:00 By Nasdaq GlobeNewswire

Esperion to Participate in H.C. Wainwright 25th Annual Global Investment Conference

28 Aug 2023 08:00:00 By Nasdaq GlobeNewswire

Esperion Presents Two CLEAR Outcomes Study Late-Breakers at European Society of Cardiology Congress 2023

26 Aug 2023 11:00:00 By Nasdaq GlobeNewswire

Two CLEAR Outcomes Study Late-Breakers Accepted at European Society of Cardiology (ESC) Congress 2023

11 Aug 2023 08:00:00 By Nasdaq GlobeNewswire

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

08 Aug 2023 16:15:00 By Nasdaq GlobeNewswire

Esperion Reports Second Quarter 2023 Financial Results

01 Aug 2023 06:00:00 By Nasdaq GlobeNewswire

Esperion to Report Second Quarter 2023 Financial Results on August 1

17 Jul 2023 06:00:00 By Nasdaq GlobeNewswire

Esperion to Present Additional Data from the CLEAR Outcomes Study on CVD Prevention at the American Society for Preventive Cardiology (ASPC) Congress 2023

07 Jul 2023 08:00:00 By Nasdaq GlobeNewswire

Esperion Announces Submission of Application for Expanded Indication with the European Medicines Agency (EMA) for NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Tablet

28 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

Esperion Presents Results from CLEAR Outcomes Primary Prevention Analysis at 83rd American Diabetes Association Scientific Sessions

24 Jun 2023 14:30:00 By Nasdaq GlobeNewswire

Esperion Presents Results from New Analysis on Cardiovascular Benefits with Bempedoic Acid Treatment at ENDO 2023

15 Jun 2023 14:30:00 By Nasdaq GlobeNewswire

Esperion to Present New Key Science at the American Diabetes Association’s 83rd Scientific Sessions 2023

08 Jun 2023 08:00:00 By Nasdaq GlobeNewswire

Esperion to Present Additional Analyses from the Landmark CLEAR Outcomes Study at ENDO 2023

05 Jun 2023 08:00:01 By Nasdaq GlobeNewswire